This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wild, S. H Articles by Byrne, C. D Search for Related Content Social Bookmarking                         What's this?

Review: Treatment of lipids to reduce cardiovascular risk among people with the metabolic syndrome or type 2 diabetes

Public Health Sciences, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG, UK

Christopher D Byrne

Level F, Centre Block (MP113- Room CF96), Southampton General Hospital, Southampton, SO16 6YD, UK, cdtb{at}soton.ac.uk

he metabolic syndrome is present in approximately 20% of general populations in developed countries and in approximately 80% of people with type 2 diabetes. High triglyceride levels, low high-density cholesterol levels and central obesity are three of the five features of the metabolic syndrome and contribute to the increased risk of cardiovascular disease (CVD) among people with the metabolic syndrome. Lifestyle interventions and treatment with statins reduce risk of CVD but absolute risk of cardiovascular events among high-risk populations remains high. This article reviews the options for treating the atherogenic dyslipidaemia associated with the metabolic syndrome.

References

• Lee WL, Cheung AM, Cape D., Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 2000;23:962-8.[Abstract]
• Wild SH, Byrne CD The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In Byrne CD, Wild SH (eds). The Metabolic Syndrome. Chichester: Wiley, 2005:1-41.
• Turner RC, Millns H., Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-8.[Abstract/Free Full Text]
• Hokanson JE, Austin MA Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-19.[Medline] [Order article via Infotrieve]
• Guzder RN, Gatling W., Mehta RL, Mullee MA, Byrne CD Prognostic Value of the framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabet Med 2005;22:55462.
• Guzder RN, Gatling W., Mullee MA, Byrne CD The impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia 2005. (In press).
• Nakanishi N., Takatorige T., Fukuda H. et al. Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men. Diabetes Res Clin Pract 2004;64:59-70.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. National Institutes of Health. Obes Res 1998;6(suppl 2):51s-209s.[Web of Science]
• Klein S., Burke LE, Bray GA et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004;110:2952-67.[Abstract/Free Full Text]
• Peeters A., Barendregt JJ, Willekens F., Mackenbach JP, Al Mamun A., Bonneux L. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003;138:24-32.[Abstract/Free Full Text]
• Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005.
• Franklin BA, Kahn JK, Gordon NF, Bonow RO A cardioprotective `polypill`? Independent and additive benefits of lifestyle modification. Am J Cardiol 2004;94:162-6.[Web of Science][Medline] [Order article via Infotrieve]
• Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366: 1267-78.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-35.[Abstract/Free Full Text]
• Cannon CP, Braunwald E., McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.[Abstract/Free Full Text]
• Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568-76.[Abstract/Free Full Text]
• Feher M., Elkeles RS Fenofibrate in type 2 diabetes: The FIELD study. Br J Diabetes Vasc Dis 2005;5:330-3.[Free Full Text]
• Keech A. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol 2005;4:13.[CrossRef][Medline] [Order article via Infotrieve]
• Dormandy JA, Charbonnel B., Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366:1279-89.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Freemantle N. How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events? BMJ 2005;331:836-8.[Free Full Text]
• Buse JB, Rubin CJ, Frederich R. et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther 2005;27:1181-95.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Clark RW, Sutfin TA, Ruggeri RB et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004;24: 490-7.[Abstract/Free Full Text]
• Brousseau ME, Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL-cholesterol. N Engl J Med 2004; 350:1505-15.[Abstract/Free Full Text]
• Avorn J. Torcetrapib and atorvastatin - should marketing drive the research agenda? N Engl J Med 2005;352:2573-6.[Free Full Text]
• Wong ND Cardiovascular risk assessment in the metabolic syndrome, screening for subclinical disease, and implications for treatment. Br J Diabetes Vasc Dis 2005;5:305-14.[Abstract/Free Full Text]
• Shepherd J., Betteridge J., Van Gaal L. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin 2005;21:665-82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• National Institute of Clinical Excellence. Management of Type 2 Diabetes - management of blood pressure and blood lipids. 2002. London, NICE.

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 6, 315-319 (2005)
DOI: 10.1177/14746514050050060301


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. J Krentz Effective management of type 2 diabetes and metabolic syndrome: beyond glucose control The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 303 - 304. [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wild, S. H Articles by Byrne, C. D Search for Related Content Social Bookmarking                         What's this?